Impact of Medical Cannabis Rescheduling on License Values

The U.S. cannabis industry just experienced its most significant federal policy shift in decades.

In April 2026, the Department of Justice issued a final order moving state-licensed medical cannabis and FDA-approved cannabis products to Schedule III under the Controlled Substances Act.

At first glance, this appears to be the long-awaited federal breakthrough. In reality, the outcome is more nuanced and more disruptive to license values and capital allocation than full legalization would have been.

At CannaMLS, we saw an immediate surge in inbound interest for medical-only licenses, particularly in markets like Florida. That reaction signals something deeper: this isn’t just a regulatory change, it’s a shift in the underlying economics of the industry.

This post breaks down what changed, what hasn’t, and how this could reshape cannabis valuations in the near term.

What Actually Happened (And What Didn’t)

The April 2026 order does not reschedule all cannabis. It creates a split federal framework:

• Schedule III (new status):
  • State-licensed medical cannabis
  • FDA-approved cannabis drugs
• Still Schedule I:
  • Adult-use (recreational) cannabis
  • Non-licensed cannabis
  • Synthetic THC products

A new DEA administrative hearing process (scheduled from late June through mid-July 2026) will determine whether all cannabis, including adult use, will be rescheduled. Until then, the industry is operating in a two-channel system.

The Immediate Impact: 280E Relief for Medical Operators

The most important change is tax-related. Under Internal Revenue Code Section 280E, cannabis businesses have historically been unable to deduct ordinary business expenses because cannabis was classified as a Schedule I substance.

With medical cannabis now in Schedule III:

• 280E no longer applies to qualifying medical operations
• Operators can take standard deductions
• Effective tax rates drop dramatically

Legal analysts describe this as an “overnight transformation of the economics of medical cannabis operations.”

For operators with meaningful medical exposure, this translates directly into:

• Higher EBITDA
• Increased free cash flow
• Improved credit profiles

Why License Values Are Already Reacting

This is where the market is moving faster than the headlines. We are already seeing:

• Increased buyer activity for medical-only licenses
• Stronger inbound interest in dual-license assets with medical exposure
• More institutional curiosity around compliant, federally-aligned operations

Why? Because the order effectively creates two different economic models within the same industry:

Segment	Federal Status	Tax Treatment
Medical	Schedule III	Normal taxation
Adult-use	Schedule I	280E still applies

That tax arbitrage alone can justify meaningfully higher valuations for medical-heavy assets.

The Complexity: Operating in a Two-Channel System

If this framework persists, operators will face a new strategic reality. A “two-channel” system introduces:

• Separate compliance structures
• Complex cost allocation between medical and adult-use revenue
• Incentives to shift sales toward medical programs
• Potential restructuring of entities and licenses

The biggest open question centers on dual-license operators. Tax law traditionally applies to the taxpayer (entity), not the product. This raises a critical and unresolved issue:

If a company holds a medical license, can it argue that its entire business is no longer subject to 280E?

Some legal commentators suggest:

• The IRS could allow segmented accounting between medical and adult-use
• Or take a stricter view and apply 280E to the entity if any Schedule I activity exists

As of today, no formal IRS guidance has been issued, leaving this as one of the most important variables in the rescheduling impact analysis.

A Hidden Signal: Federal Legitimacy

Beyond taxes, rescheduling introduces something the industry has never truly had: Federal acknowledgment of state-licensed cannabis businesses.

The order creates a pathway for:

• DEA registration for medical operators
• Potential international export (for medical/scientific purposes)
• Greater regulatory clarity

Equity research analysts have described this as providing “federal cover”, which could:

• Improve banking relationships
• Reduce perceived legal risk
• Lay groundwork for eventual institutional capital entry

This matters for valuations.

What Happens Next Will Drive Everything

The upcoming DEA hearing (June–July 2026) is now the key catalyst. There are two primary paths forward:

Scenario 1: Full Rescheduling (Medical + Adult Use)

If all cannabis moves to Schedule III:

• 280E disappears across the entire industry
• Institutional capital becomes more viable
• Cost of capital begins to decline
• M&A activity accelerates

In this scenario, we expect broad-based valuation expansion across all license types.

Scenario 2: Medical-Only Rescheduling Persists

If adult-use rescheduling is delayed or blocked:

• The two-channel system remains in place
• Medical licenses become structurally advantaged
• Operators are incentivized to:
  • Expand medical programs
  • Reallocate sales channels
  • Pursue medical licensure in new states

In this scenario, we expect premium valuations for medical licenses and medical-heavy operators, with capital flowing disproportionately into those assets.

What This Means for Buyers, Sellers, and Investors

This moment is less about what the law says today, and more about how capital is positioning for what comes next.

Near-term:

• Medical license demand is increasing
• Valuation gaps between medical and adult-use assets may widen

Medium-term:

• Structuring, tax strategy, and license mix will become key value drivers

Long term:

• If full rescheduling occurs, the industry could see:
  • Institutional capital inflows
  • Lower financing costs
  • A fundamental repricing of cannabis assets

Final Takeaway

The April 2026 rescheduling order is not full legalization. But it is a structural shift in the economics of cannabis businesses.

For now, that shift benefits only part of the market.

Whether it expands to the entire industry, or creates a prolonged divide between medical and adult-use operations, will determine where capital flows next.

Stay tuned!

Sources:

• DOJ Final Order on Rescheduling (April 2026)
• Dentons Rescheduling Legal Analysis (April 2026)
• Zuanic & Associates Equity Research (April 2026)
• Cultivated Daily Rescheduling Commentary (April 2026)